<DOC>
	<DOCNO>NCT00509457</DOCNO>
	<brief_summary>To examine safety efficacy telomerase peptide vaccination ( stimulation immune system ) patient NSCLC treat conventional therapy radiotherapy docetaxel radiosensitizer .</brief_summary>
	<brief_title>GV 1001 Immunotherapy Patients With Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>Survival patient locally advance , inoperable NSCLC may improve local control achieve concurrent chemo radiotherapy .After complete standard chemo-and radiation therapy ; safety efficacy vaccination therapy measure time progression treatment GV1001 . Analysis change T-cell subpopulation cytokine peripheral blood perform .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Patients inoperable NSCLC , disease stage IIIA stage IIIB , receive concurrent chemoradiotherapy ( typically docetaxel 20 mg/m2 3D radiotherapy , 2Gy x 30 within last 4 week . No sign brain metastasis ( exclude MRI brain ) Male female age 18 year . Normal lab . value</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>NSCLC , vaccination</keyword>
	<keyword>Inoperable NSCLC stage IIIA/B good performance status</keyword>
</DOC>